Michael Ryskin is a Managing Director in Bank of America Equity Research covering the Life Science Tools & Diagnostics sector. He ranked in third place in the 2024 Institutional Investor All-America Research Survey (the BofA Life Science Tools team ranked #1 as a team) and has been II ranked since 2022. Previously, he was a research scientist at Pfizer in the Oncology Research Unit, where he performed pre-clinical drug discovery. He received a Bachelor's degree in molecular biology from Cornell University and a Master's in the same subject from Brown University, as well as an MBA from New York University.